We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
BEVESPI AEROSPHERE (AstraZeneca Pty Ltd)
Product name
BEVESPI AEROSPHERE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
228 working days (255)
Active ingredients
glycopyrronium bromide (glycopyrrolate); formoterol (eformoterol) fumarate dihydrate
Registration type
EOI
Indication
New combination
BEVESPI AEROSPHERE (inhaler) is indicated as a long-term twice-daily maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD).